Recent reports suggest that the efficacy of antidepressant medications compared with placebo may be overstated owing to publication bias
1 and that antidepressants have less efficacy for mildly depressed patients.
2,3 For example,
1 of 74 US Food and Drug Administration–registered randomized controlled trials (RCTs) involving 12 antidepressants in 12 564 patients, 94% of published trials were positive, whereas only 51% of all US Food and Drug Administration–registered studies were positive. A meta-analysis
2 of 35 RCTs of 4 antidepressants (fluoxetine hydrochloride, venlafaxine hydrochloride, nefazodone hydrochloride, and paroxetine hydrochloride) found that only studies with higher average baseline severity achieved the putative clinically significant 3-point difference in Hamilton Depression Scale (HAM-D) scores.
4 A study
3 of individual-level data from 6 RCTs comparing paroxetine or imipramine hydrochloride with placebo concluded that there was benefit only for those with very severe depression.